Nasdaq Spro News Today

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totalling 680,200 shares, a drop of 13.8% from the December 31st total of 789,000 shares. Based on an average daily volume of 171,200 shares, the days-to-cover ratio […]

In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in...

$95 million in development milestones payable over two years, as part of GSK license agreement...

Cantor Fitzgerald reissued their overweight rating on shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) in a report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Spero Therapeutics’ FY2024 earnings at ($0.85) EPS. Separately, HC Wainwright restated a buy rating and set a $7.00 price objective on shares of Spero Therapeutics […]

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.39 and traded as low as $1.14. Spero Therapeutics shares last traded at $1.17, with a volume of 166,122 shares traded. Wall Street Analyst Weigh In […]

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.53 and traded as low as $1.12. Spero Therapeutics shares last traded at $1.15, with a volume of 78,492 shares. Analyst Ratings Changes Separately, HC Wainwright reiterated […]

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 1,430,000 shares, an increase of 25.4% from the August 31st total of 1,140,000 shares. Based on an average trading volume of 336,400 shares, […]

HC Wainwright reaffirmed their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock. Spero Therapeutics Trading Up 1.5 % NASDAQ SPRO opened at $1.36 on Tuesday. Spero Therapeutics has a fifty-two week […]

Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) – Research analysts at HC Wainwright reduced their Q4 2023 EPS estimates for shares of Spero Therapeutics in a research note issued to investors on Monday, August 14th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.50 for the quarter, […]

Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) – Investment analysts at HC Wainwright boosted their Q2 2023 earnings estimates for shares of Spero Therapeutics in a research report issued to clients and investors on Thursday, July 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.28) per share for […]